Sleep Duration and Risk of Lung Cancer in the Physicians' Health Study

Owais KHAWAJA1, Andrew B. PETRONE2, Sohaib ALEEM3, Kamran MANZOOR1, John M GAZIANO2,4,5,6, Luc DJOUSSE2,4,6

1Section of Pulmonary and Critical Care Medicine, Dartmouth Hitchcock Medical Center, Lebanon, USA; 2Divisions of Aging, Brigham and Women's Hospital and Harvard Medical School, Boston, USA; 3Section of General Internal Medicine, Dartmouth Hitchcock Medical Center, Lebanon, USA; 4Massachusetts Veterans Epidemiology and Research Information Center (MAVERIC), Boston Veterans Affairs Healthcare System, Boston, USA; 5Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA; 6Geriatric Research, Education, and Clinical Center (GRECC), Boston Veterans Affairs Healthcare System, Boston, USA

Abstract

Background and Objectives: Lung cancer is the most common cancer and cancer related cause of death worldwide. However, the association between sleep duration and incident lung cancer has not been investigated in a prospective cohort study.

Methods: We prospectively examined the association between sleep duration and incident lung cancer in a cohort of 21,026 United States (US) male physicians. Self-reported sleep duration was ascertained during 2002 annual follow-up questionnaire. Incident lung cancer was ascertained through yearly follow-up questionnaires. Cox regression was used to estimate relative risk of incident lung cancer.

Results: The average age at baseline was 68.3±8.8 yr. During a mean follow up of 7.5 (±2.2) yr, 150 cases of lung cancer occurred. Using 7 h of sleep as the reference group, multivariable adjusted hazard ratios (95%CI) for lung cancer were 1.18 (0.77-1.82), 1.0 (ref), and 0.97 (0.67-1.41) from lowest to the highest category of sleep duration (P for quadratic trend 0.697), respectively. In a secondary analysis, smoking status did not modify the sleep duration-lung cancer association (P=0.78). There was no evidence for an interaction between sleep duration and sleep apnea on the risk of lung cancer either (P=0.65).

Conclusions: Our data failed to show a higher risk of lung cancer in association with altered sleep duration among US male physicians.

Key words Sleep; Lung neoplasms; Risk factors; Epidemiology

Introduction

Lung cancer is the most common cancer and cancer related cause of death worldwide[1]. Lung cancer has also been the leading cause of cancer related death in United States of America (USA)[2]. As per an estimate, there will be approximately 228,190 individuals diagnosed with, and 159,480 individuals dying of lung cancer in 2013[3]. Data from prior studies have demonstrated positive associations with genetic predisposition[4,5], occupational exposures[6], inflammation[7,8], type 2 diabetes (T2D)[9,10], alcohol consumption[4,11], and most importantly smoking[12] while beneficial effects of dietary factors[13,14], obesity[15], and medium or high levels of physical activity[16] on lung cancer risk have been reported. Among occupational exposures associated with increased risk of lung cancer include those involved with production of industrial machinery, metallurgical industry, ceramics industry, textile industry, rubber industry, and plastic industry among others[6].

Others studies have demonstrated an increased risk of cancer and cancer related mortality in association with sleep disordered breathing (SDB)[17,18]. Alterations in circadian rhythm has been associated with various aspects of carcinogenesis[19,20]. Recently, study on a prospective cohort of Nurses’ Health Study demonstrated a higher incidence of lung cancer with extended night-shift work among smokers[21]. In another study, a higher incidence of various cancers, including lung cancer was demonstrated among men who ever worked at night[22]. Alterations in sleep duration has also been associated with smoking[23], alcohol consumption[24], physical activity[25], obesity[26], inflammation[27,28], T2D[29], SDB[30], and cancer related

www.lungca.org
mortality\(^{[31]}\).

However, to the best of our knowledge, the association between sleep duration and incident lung cancer has not been investigated in a prospective cohort study. Therefore, the current study sought to prospectively assess the association of sleep duration with the risk of lung cancer among US male physicians.

**Methods**

The Physicians’ Health Study (PHS) I is a completed randomized, double-blind, placebo-controlled trial, designed to study the effects of low-dose aspirin (ASA) and beta-carotene on cardiovascular disease (CVD) and cancer among US male physicians. In 1997, PHS II trial enrolled 7,641 physicians from PHS I along with 7,000 new physicians to study the effects of vitamins on CVD and cancer. A detailed description of the PHS I and II has been published\(^{[26,32]}\). Self-reported sleep duration was ascertained during the 2002 annual follow-up questionnaire which served as the baseline for our study. Of the total 29,067 PHS subjects, we excluded people with prevalent lung cancer (n=63), and those who died before sleep duration assessment or had no follow-up (n=845), and those with missing data on sleep duration (n=7,133). Thus, a final sample of 21,026 participants was used for current analyses. Each participant gave written informed consent and the Institutional Review Board at Brigham and Women’s Hospital approved the study protocol.

For self-reported sleep duration, participants were asked: “On average, how many total hours of sleep do you get in typical 24-h period?” Possible responses were “<5 h”, “6 h”, “7 h”, “8 h”, “9 h”, “10 h”, and “11+ h”.

Incident cancer was ascertained through yearly follow-up questionnaires. Participants were asked: Since you filled out the last questionnaire (about 12 mo ago), were you newly diagnosed as having any of the following conditions? (Please mark No or Yes). One of the possible responses was, “Cancer (Non-skin). Site_____. Date of Diagnosis”. All cancer cases were ascertained and validated by medical record review by the PHS II Endpoints Committee composed of physicians blinded to treatment assignment; 96.9% of confirmed total cancers were based on pathology or cytology reports. Cases of cancer were otherwise confirmed based upon strong clinical and radiological or laboratory marker evidence. Only confirmed cancer cases are included in this report.

Data on demographics, anthropometrics, exercise frequency, smoking, and alcohol consumption, along with history of T2D, sleep apnea, and snoring were obtained at baseline (i.e. 2002). If the data was not available at the baseline than the information from as close to sleep assessment as possible (usually from 12 mo prior questionnaire) was obtained. Age and body mass index (BMI) were used as continuous variables. Race was dichotomized as white vs non-white. Exercise was classified as rarely/never, 1-3 times/mo, 1-4/wk, and 5-7/wk. Smoking was classified as never, past, and current smokers. For alcohol consumption, subjects were asked the following question: “How often do you usually consume alcoholic beverages?” Possible responses were: rarely/never, 1-3 times/mo, 1 time/wk, 2-4 times/wk, 5-6 times/wk, daily, and ≥2 times/d. These responses were interpreted as the number of alcoholic drinks consumed during the specified period. For current analyses, alcohol consumption was classified as <1, 1-4, 5-7, and >7 drinks/wk. Diagnosis of T2D was self-reported and validated by detailed review of the medical records in a subsample\(^{[34]}\). Diagnosis of sleep apnea (Yes vs No) and snoring (rarely/never, few/occasionally, mostly/always, and unknown/missing), parental history of cancer, and caloric intake were based on self-reported information. For categorical variables, indicator values were created for missing observations.

We classified each subject into one of the following categories of average sleep duration: <6 h, 7 h, and ≥8 h. We computed person-time of follow up from the time when sleep duration was assessed until the first occurrence of a) confirmed lung cancer, b) death, or c) the date of last available follow up (August 1st, 2011). Baseline demographic variables were recorded and compared across categories of sleep duration.

We used Cox proportional hazard models to compute multivariable adjusted hazard ratios (HR) with corresponding 95% confidence intervals (CI) using participants reporting 7 h of sleep duration as the reference group. Potential confounding was assessed for established risk factors of lung cancer. First, we adjusted for age and race in model 1. Second, we also controlled for parental history of cancer, exercise frequency, caloric intake, BMI, T2D, alcohol consumption, smoking status, sleep apnea, and snoring in model 2.

To further address confounding by age we calculated age-standardized incidence rate for lung cancer using year 2000 US Standard Population. In secondary analyses, we evaluated whether there were statistically significant interactions between sleep duration and smoking status or sleep apnea by using a product term of both variables in a hierarchical model. Assumptions for proportional hazard models were tested (by including main effects and product terms of sleep duration and logarithmic-transformed time factor) and were met for all variables except snoring (\(P>0.05\)). Therefore, snoring was included in a strata statement in the model. All analyses were conducted using SAS, version 9.2 (SAS Institute, NC). Significance level was set at 0.05 (two-sided.
test).

**Results**

Table 1 shows baseline characteristics according to sleep duration. Mean age of the study participants at baseline was 68.3±8.8 yr. Long (>8 h) sleep duration was associated with a lower prevalence of never smokers and frequent snoring; and a higher prevalence of elderly, white, >7/wk alcohol consumption, T2D, and higher caloric intake.

Table 2 shows a comparison of the baseline characteristics between subjects with missing data on sleep duration (after excluding those who died before the assessment of baseline information and those with prevalent lung cancer) and those with complete data on sleep duration. Overall, there was higher prevalence of lung cancer among those with missing sleep duration than otherwise (293 vs 150 cases, respectively). The participants with missing data on sleep duration were more likely to be older; current smokers, heavy alcohol drinkers (>7/wk), had a higher prevalence of sleep apnea, and sedentary lifestyle. They however were less likely to have parental history of cancer and had a lower caloric intake compared to people with complete data on sleep duration.

During a mean follow up of 7.5 (±2.2) yr, 150 cases of lung cancer were diagnosed. Crude incidence rates of lung cancer were 0.86, 0.80, and 1.21 cases/1,000 person-years for people reporting an average sleep duration of <6 h, 7 h, and >8 h, respectively (Table 3). Using 7 h of sleep as the reference group, multivariable adjusted hazard ratios (95%CI) for lung cancer were 1.18 (0.77-1.82), 1.0 (ref), and 0.97 (0.67-1.41) from lowest to the highest category of sleep duration (P for quadratic trend 0.697), respectively (Table 3).
### Tab 2 Comparison of baseline characteristics between those with missing and people with complete data on sleep duration

| Variables                  | Availability of data on sleep duration | P value |
|----------------------------|----------------------------------------|---------|
|                            | No (n=7,133)                           |         |
|                            | Yes (n=21,026)                         |         |
| Age (mean±SD)              | 70.4±9.3                               | <0.001,1|
| Body mass index (mean±SD)  | 25.3±3.8                               | <0.001,1|
| Race (% White)             | 3,945 (89.7)                           | 0.001   |
| Smoking (%)                | <0.001,1                               |         |
| Never                      | 2,053 (46.6)                           |         |
| Past                       | 2,150 (48.7)                           |         |
| Current                    | 207 (4.7)                              |         |
| Exercise frequency (%)     | <0.001,1                               |         |
| Rarely/never               | 1,880 (44.2)                           |         |
| 1-3/mo                     | 102 (2.4)                              |         |
| 1-4/wk                     | 1,568 (36.9)                           |         |
| 5-7/wk                     | 702 (16.5)                             |         |
| Alcohol consumption (drinks/wk) (%) | <0.001,1 |         |
| <1/wk                      | 1,450 (34.4)                           |         |
| 1-4/wk                     | 1,101 (26.1)                           |         |
| 5-7/wk                     | 935 (22.1)                             |         |
| >7/wk                      | 732 (17.4)                             |         |
| History of snoring (%)     | <0.001,1                               |         |
| Rarely/never               | 84 (1.2)                               |         |
| Few/occasionally           | 173 (2.4)                              |         |
| Mostly/always              | 143 (2.0)                              |         |
| Unknown/missing            | 6,733 (94.4)                           |         |
| Sleep apnea (%)            | 85 (5.8)                               | 0.007   |
| Prevalent diabetes (%)     | 784 (11.0)                             | <0.001,1|
| Parental history of cancer (%) | 1,019 (51.36) | 0.036   |
| Calories (median, IQR)     | 1,588 (1,261-1,908)                    | <0.001,1|
|                            | 1,616 (1,312-1,987)                    |         |

### Tab 3 Hazard ratios (95%CI) for lung cancer according to average sleep duration in Physicians’ Health Study

| Sleep duration (h) | Cases/person-years | Crude incidence rate (per 1,000 person-yrs) | Unadjusted | Hazards ratio (95%CI) |
|--------------------|--------------------|---------------------------------------------|------------|------------------------|
|                    |                    |                                             |            | Model 1                | Model 2                |
| <6.0               | 35/40,582          | 0.86                                        | 1.08 (0.71-1.66) | 1.25 (0.82-1.92) | 1.18 (0.77-1.82) |
| 7.0                | 53/66,352          | 0.80                                        | 1.0        | 1.0                    | 1.0                    |
| >8.0               | 62/51,345          | 1.21                                        | 1.52 (1.05-2.19) | 1.11 (0.76-1.60) | 0.97 (0.67-1.41) |

P for quadratic trend: 0.155

Model 1: Age (<60, 60–<65, 65–<70, 70–<75, 75+), race (white/non-white), parental history of cancer (yes/no), exercise frequency (Never/Rarely, 1-3/mo, 1-4/wk, 5-7/wk), caloric intake (tertiles), body mass index (continuous), type 2 diabetes (yes/no), alcohol consumption (<1/wk, 1-4/wk, 5-7/wk, >7/wk), smoking status (never, past, current), sleep apnea (yes/no), and snoring (mostly/always, few/occasionally, rarely/never, unknown/missing), alcohol consumption (<1/wk, 1-4/wk, 5-7/wk, >7/wk), smoking status (never, past, current), sleep apnea (yes/no), and snoring (mostly/always, few/occasionally, rarely/never, unknown/missing).
The incidence rates for lung cancer from lowest to highest category of sleep duration were 8.62, 7.99, and 12.08 cases per 10,000 person years. Age-standardized incidence rates (95%CI) were 10.0 (6.4-13.6), 7.4 (5.3-9.6), and 8.3 (6.0-10.7), respectively. In a secondary analysis smoking status did not modify the sleep duration-lung cancer association ($P=0.78$). There was no evidence for an interaction between sleep duration and sleep apnea on the risk of lung cancer either ($P=0.65$).

**Discussion**

Our findings do not support an association of incident lung cancer with self-reported sleep duration among US male physicians. In a secondary analysis, stratification by smoking status failed to show an association between sleep duration and incidence of lung cancer. To the best of our knowledge, this is the first prospective study to assess the association between sleep duration and incident lung cancer.

There has been no prior study looking into the direct association between sleep duration and risk of lung cancer. However, there have been some studies providing an indirect support for an association between sleep duration and risk of lung cancer. Schernhammer et al\cite{21}, in a prospective cohort of Nurses’ Health Study demonstrated an increased risk of lung cancer among women who spent $\geq 15$ yr working rotating night shifts [relative risk (RR)]=1.28 (95%CI: 1.07-1.53)]. In an additional analysis the increased risk associated with $\geq 15$ years of rotating night-shift work was limited to current smokers [RR=1.61 (95%CI: 1.21-2.13)].

Parent et al\cite{22}, in a prior case-control study demonstrated a higher incidence of various cancers, including lung cancer [odd ratio (OR)=1.76 (95%CI: 1.25-2.47)], among men who ever worked at night compared to those who never did. However, they failed to show an increased risk of cancer with increased duration of night work. Also, the risk for lung cancer was not significant anymore for those who have been engaged in night work for more than 10 yr.

Despite a lack of association between sleep duration and incident lung cancer, alteration in sleep duration has been associated with factors considered important for developing lung cancer. Melatonin, secreted by pineal gland plays an important role in the regulation of circadian rhythm\cite{35}. A lower level of melatonin has been associated with short sleep duration\cite{36}. It has been demonstrated to act as a direct free radical scavenger, an indirect antioxidant, and as an important immunomodulatory agent\cite{37,38}. In a prior cross sectional study among human patients, a lower level of melatonin was demonstrated among those with non small cell lung cancer\cite{39}.

In another study flattening of diurnal cortisol rhythm, an indicator of abnormal circadian rhythm was demonstrated to be associated with worse prognosis among lung cancer patients\cite{40}. Impairment in natural killer cell function, which play a critical role in cancer immunosurveillance, has also been associated with chronic circadian disruption in animal studies\cite{41}.

Our study has some limitations. Information on average hours of sleep duration was self-reported and was assessed just once during the study period. There is no data on the quality of sleep. We do not know if reported sleep duration represented time spent in bed or actual sleep duration. We did not have information on the pathologic sub-types of lung cancer. Furthermore, participants in this study were male and mostly Caucasian physicians, thereby limiting the generalizability of our findings to general population. Nevertheless, the large sample size, more than 5 years of follow up, a standardized and systematic collection of covariates, availability of a large number of covariates, and a validation of lung cancer cases and comorbidities in the PHS are strengths of this study.

**Conclusion**

In conclusion, our study failed to show a higher risk of lung cancer in association with altered sleep duration among US male physicians.

**Acknowledgements**

We are indebted to the participants in the PHS for their outstanding commitment and cooperation and to the entire PHS staff for their expert and unfailing assistance. The Physicians’ Health Study is supported by grants CA-34944, CA-40360 and CA-097193 from the National Cancer Institute and grants HL-26490, and HL-34595, from the National Heart, Lung and Blood Institute of Health, Bethesda, MD. Funding agencies play no role in the data collection, analysis and manuscript preparation.

**References**

1. World Health Organization. Fact Sheet No 297: Cancer. February 2012.
2. American Cancer Society. Cancer Facts and Figures, 2013.
3. [http://seer.cancer.gov/csr/1975_2010/results_single/sect_01_table01.pdf](http://seer.cancer.gov/csr/1975_2010/results_single/sect_01_table01.pdf).
4. Tse I A, Yu IT, Wang XR, et al. Synergistic effect between alcohol consumption and familial susceptibility on lung cancer risk among...
13. Prizment AE, Folsom AR, Dreyfus J, et al. Plasma C-reactive protein, genetic risk score, and risk of common cancers in the atherosclerosis risk in communities study. Cancer Causes Control, 2013, 24(12): 2077-2087.

14. Guo YZ, Pan L, Du CJ, et al. Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. Asian Pac J Cancer Prev, 2013, 14(1): 243-248.

15. Pallis AG, Syrigos KN. Lung cancer in never smokers: disease characteristics and risk factors. Crit Rev Oncol Hematol, 2013, pii: S1040-8428(13)00154-6.

16. Lee JY, Jeon I, Lee JM, et al. Diabetes mellitus as an independent risk factor for lung cancer: a meta-analysis of observational studies. Eur J Cancer, 2013, 49(10): 2411-2423.

17. Tran HN, Li Y, Siu S, et al. Predictors of lung cancer: noteworthy cell type differences. Perm J, 2013, 17(2): 23-29.

18. Alberg AJ, Brock MV, Ford JG, et al. Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2013, 143(Suppl): e1S-29S.

19. Gallicchio L, Kalesan B. Sleep duration and mortality: a systematic review and meta-analysis. J Sleep Res, 2009, 18(2): 148-158.

20. Christen WG, Gaziano JM. Relation between modifiable lifestyle factors and lifetime risk of heart failure. JAMA, 2009, 302: 394-400.

21. Gallicchio L, Gaziano JM, Hennekens CH. Design of Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. JAMA, 2006, 295(8): 956-961.

22. Gallicchio L, Gaziano JM, Hennekens CH. Design of Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. JAMA, 2006, 295(8): 956-961.

23. McNamara JP, Wang J, Holiday DB, et al. Sleep disturbances associated with cigarette smoking. Psychol Med, 2014, 19(4): 410-419.

24. Galli G, Piaggi P, Mattiello MS, et al. Inverse relationship of food and alcohol intake to sleep measures in obesity. Obes Res, 2003, 11: 1357-1362.

25. Baron KG, Reid KJ, Zee PC. Exercise to improve sleep in insomnia: exploration of the bidirectional effects. J Clin Sleep Med, 2013, 9(8): 819-824.

26. Xiao Q, Arem H, Moore SC, et al. A large prospective investigation of sleep duration, weight change, and obesity in the NIH-AARP diet and health study cohort. Am J Epidemiol, 2013, 178(11): 1600-1610.

27. Grandner MA, Sands-Lincoln MR, Pak VM, et al. Sleep duration, cardiovascular disease, and proinflammatory biomarkers. Nat Sci Sleep, 2013, 5: 93-107.

28. Ferrie JE, Kivimaki M, Akbaraly TN, et al. Associations between change in sleep duration and inflammation: findings on C-reactive protein and interleukin 6 in the Whitehall II Study. Am J Epidemiol, 2013, 178(6): 956-961.

29. Jackson CI, Redline S, Kawachi I, et al. Association between sleep duration and diabetes in Black and White adults. Diabetes Care, 2013, 36(11): 3557-3565.

30. Hargens TA, Kaleath AS, Edwards ES, et al. Association between sleep disorders, obesity, and exercise: a review. Nat Sci Sleep, 2013, 5: 27-35.

31. Gallicchio L, Kalesan B. Sleep duration and mortality: a systematic review and meta-analysis. J Sleep Res, 2009, 18(2): 148-158.

32. Christen WG, Gaziano JM, Hennekens CH. Design of Physicians’ Health Study II—a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol, 2000, 10(2): 125-134.

33. Bode RL, Vittinghoff E, et al. Final report on the aspirin component of the ongoing Physicians’ Health Study. JAMA, 2006, 295(8): 956-961.

34. Gallicchio L, Gaziano JM, Hennekens CH. Design of Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. JAMA, 2006, 295(8): 956-961.

35. Brzezinski A. Melatonin in humans. N Engl J Med, 1997, 336(3): 186-195.

36. Aeschbach D, Deslauriers D, Postolache TT, et al. Rotating night-shift work and long sleepers than in short sleepers. J Clin Endocrinol Metab, 2003, 88(1): 26-30.

37. Vijayalaxmi, Thomas CR Jr, Reiter RJ, et al. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol, 2002, 20(10): 2575-2601.

38. Anisimov VN, Popovich IG, Zabiezhinski MA, et al. Melatonin as antioxidant, geroprotector and anticarcinogen. Biochem Biophys Acta, 2000, 1757(5-6): 573-589.

39. Hsu S, Shen G, Yin S, et al. Melatonin and tryptophan circadian profiles in patients with advanced non-small cell lung cancer. Adv Ther, 2009, 26(9): 886-892.

40. Kim KS, Kim YC, Oh JH, et al. Association of worse prognosis with an
aberrant diurnal cortisol rhythm in patients with advanced lung cancer. Immunol, 2012, 188(6): 2583-2591.

Logan RW, Zhang C, Murugan S, et al. Chronic shift-lag alters the circadian clock of NK cells and promotes lung cancer growth in rats. J Immunol, 2012, 188(6): 2583-2591.

(Received: 2014-06-23   Accepted: 2014-07-15)

(Edited by Juan NAN)

Cite this article as: Khawaja O, Petrone AB, Aleem S, et al. Sleep Duration and Risk of Lung Cancer in the Physicians' Health Study. Zhongguo Fei Ai Za Zhi, 2014, 17(9): 649-655. doi: 10.3779/j.issn.1009-3419.2014.09.02.

中国肺癌杂志2014年9月第17卷第9期  Chin J Lung Cancer, September 2014, Vol.17, No.9